Compare NRXS & TENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NRXS | TENX |
|---|---|---|
| Founded | 2011 | 1967 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 76.9M | 73.8M |
| IPO Year | 2023 | 2001 |
| Metric | NRXS | TENX |
|---|---|---|
| Price | $4.44 | $1.35 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 10 |
| Target Price | ★ $11.00 | $10.29 |
| AVG Volume (30 Days) | 146.5K | ★ 1.3M |
| Earning Date | 11-09-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 22.13 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,569,282.00 | N/A |
| Revenue This Year | $118.53 | N/A |
| Revenue Next Year | $101.28 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 32.89 | N/A |
| 52 Week Low | $2.50 | $1.31 |
| 52 Week High | $9.33 | $19.40 |
| Indicator | NRXS | TENX |
|---|---|---|
| Relative Strength Index (RSI) | N/A | N/A |
| Support Level | N/A | N/A |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.00 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 0.00 |
Neuraxis Inc is a growth-stage medical technology company focused on neuromodulation therapies for chronic and debilitating conditions in the gastrointestinal (GI) digestive system, specifically from disorders of the gut-brain interaction (DGBIs) in pediatrics and adults. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).
Tenax Therapeutics Inc is a phase three, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardiovascular and pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension. Its drug development pipeline comprises: Levosimendan, a novel, first-in-class K-ATP activator and calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure; and Imatinib, as a potential therapy for pulmonary arterial hypertension. The company is currently conducting clinical trials only for levosimendan as its prioritized product candidate to evaluate its potential to help patients with pulmonary hypertension.